Komori
StemCell Institute (7096) · PolicyRestated

Change in Installment Fee Revenue Recognition Resulting from the Application of the Accounting Standard for Revenue Recognition

First written in FY2022-Q1. 5 of 6 entries say "Restated". Latest entry: FY2026.

6entries
6years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2022-Q1 – FY20262021: 220212022: 120222023: 120232024: 020242025: 120252026: 12026
Same theme, other companies

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2026RestatedAnnual report

    「Under its contracts with customers, the Company is required to take custody of cells from customers and store the cells separated or processed by the Company throughout the contract period. Because this performance obligation is satisfied over time, revenue is recognized on a prorated basis over the contract period.」

    The Company continues to recognize revenue from cell separation and processing upon completion and storage fees over the contract period.
  2. FY2025RestatedAnnual report

    「The Company has applied the Accounting Standard for Revenue Recognition (ASBJ Statement No. 29, 31 March 2020) and other relevant standards from the beginning of fiscal year 23. Accordingly, the key management indicators and other figures for fiscal year 23 onward are based on the standards after their application.」

    The Company continues to apply the Revenue Recognition Standard adopted from the beginning of fiscal year 23.
  3. FY2023RestatedAnnual report

    「The Company has applied the Accounting Standard for Revenue Recognition (ASBJ Statement No. 29, 31 March 2020) and other relevant standards from the beginning of fiscal year 23. Accordingly, the key management indicators and other figures for fiscal year 23 onward are based on the standards after their application.」

    The Company continues to apply the Revenue Recognition Standard adopted from the beginning of fiscal year 23.
  4. FY2022RestatedAnnual report

    「The adoption of the Revenue Recognition Standard and other relevant standards increased sales, operating profit, ordinary profit and profit before income taxes by ¥7.691 million each.」

    The Company continues to apply the Revenue Recognition Standard and reports the impact on each profit measure for the fiscal year as ¥7.691 million.
  5. FY2022-Q2RestatedAnnual report

    「From the beginning of the first quarter accounting period, we adopted the Accounting Standard for Revenue Recognition (Accounting Standard No. 29, 31 March 2020; hereinafter, the “Revenue Recognition Standard”) and related standards. Revenue is recognized at the amount expected to be received in exchange for the promised goods or services when control of those goods or services transfers to the customer.」

    The Company continues to apply the Revenue Recognition Standard adopted from the first quarter. It is stated that, for the cumulative period of the second quarter, sales and other amounts increased by ¥3.306 million, while retained earnings at the beginning of the fiscal year decreased by ¥11.923 million.
  6. FY2022-Q1First statedAnnual report

    「The Company has applied the Accounting Standard for Revenue Recognition (ASBJ Statement No. 29, 31 March 2020) and other relevant standards from the beginning of the first quarter of the current fiscal year. Revenue is recognized at the point when control of the promised goods or services is transferred to the customer, at the amount expected to be received in exchange for those goods or services. Accordingly, whereas installment fees related to installment payments were previously recognized as revenue when cells were separated, the Company has changed to a method of recognizing revenue over the installment contract period.」

    The Company applied the Revenue Recognition Standard from the beginning of the first quarter of fiscal 2021 and changed the timing of installment-fee recognition. As a result of the adoption, sales and other amounts for the cumulative period of the quarter increased by ¥2.946 million, while retained earnings at the beginning of the fiscal year decreased by ¥11.923 million.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for StemCell Institute yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.